Oxurion NV (OXUR.BR)

EUR 0.27

(0.0%)

Long Term Debt Summary of Oxurion NV

  • Oxurion NV's latest annual long term debt in 2023 was 117 Thousand EUR , down -96.38% from previous year.
  • Oxurion NV's latest quarterly long term debt in 2024 Q2 was - EUR , down 0.0% from previous quarter.
  • Oxurion NV reported annual long term debt of 3.23 Million EUR in 2022, down -61.64% from previous year.
  • Oxurion NV reported annual long term debt of 8.43 Million EUR in 2021, up 1786.58% from previous year.
  • Oxurion NV reported quarterly long term debt of 117 Thousand EUR for 2023 FY, down -96.38% from previous quarter.
  • Oxurion NV reported quarterly long term debt of 117 Thousand EUR for 2023 Q4, down 0.0% from previous quarter.

Annual Long Term Debt Chart of Oxurion NV (2023 - 2006)

Historical Annual Long Term Debt of Oxurion NV (2023 - 2006)

Year Long Term Debt Long Term Debt Growth
2023 117 Thousand EUR -96.38%
2022 3.23 Million EUR -61.64%
2021 8.43 Million EUR 1786.58%
2020 447 Thousand EUR -66.52%
2019 1.33 Million EUR 0.0%
2018 - EUR 0.0%
2017 - EUR 0.0%
2016 - EUR 0.0%
2015 - EUR 0.0%
2014 - EUR 0.0%
2013 - EUR 0.0%
2012 - EUR 0.0%
2011 - EUR 0.0%
2010 - EUR 0.0%
2009 - EUR 0.0%
2008 - EUR 0.0%
2007 - EUR 0.0%
2006 - EUR 0.0%

Peer Long Term Debt Comparison of Oxurion NV

Name Long Term Debt Long Term Debt Difference
ABIONYX Pharma SA 1.1 Million EUR 89.373%
ABIVAX Société Anonyme 44.69 Million EUR 99.738%
Adocia SA 4.54 Million EUR 97.423%
Aelis Farma SA 2.04 Million EUR 94.287%
Biophytis S.A. 3.11 Million EUR 96.239%
Advicenne S.A. 15.89 Million EUR 99.264%
genOway Société anonyme 5.51 Million EUR 97.88%
IntegraGen SA 642.28 Thousand EUR 81.784%
Medesis Pharma S.A. 1.2 Million EUR 90.25%
Neovacs S.A. 650 Thousand EUR 82.0%
NFL Biosciences SA 39.2 Thousand EUR -198.447%
Plant Advanced Technologies SA 4.35 Million EUR 97.314%
Quantum Genomics Société Anonyme 1.96 Million EUR 94.032%
Sensorion SA 1.24 Million EUR 90.571%
Theranexus Société Anonyme 2.46 Million EUR 95.245%
TME Pharma N.V. - EUR -Infinity%
Valbiotis SA 3.89 Million EUR 96.998%
TheraVet SA 1 Million EUR 88.307%
Valerio Therapeutics Société anonyme 6.9 Million EUR 98.306%
argenx SE 15.35 Million EUR 99.238%
BioSenic S.A. 15.57 Million EUR 99.249%
Celyad Oncology SA 902 Thousand EUR 87.029%
DBV Technologies S.A. 4.52 Million USD 97.415%
Galapagos NV 4.94 Million EUR 97.633%
Genfit S.A. 62.25 Million EUR 99.812%
GeNeuro SA 6.49 Million EUR 98.198%
Hyloris Pharmaceuticals SA 344 Thousand EUR 65.988%
Innate Pharma S.A. 30.6 Million EUR 99.618%
Inventiva S.A. 25.61 Million EUR 99.543%
MaaT Pharma SA 5.42 Million EUR 97.843%
MedinCell S.A. 52.8 Million EUR 99.778%
Nanobiotix S.A. 41.66 Million EUR 99.719%
Onward Medical N.V. 16.3 Million EUR 99.282%
Oryzon Genomics S.A. 3.45 Million EUR 96.609%
OSE Immunotherapeutics SA 35.5 Million EUR 99.67%
Pharming Group N.V. 123.65 Million EUR 99.905%
Poxel S.A. 40.14 Million EUR 99.709%
GenSight Biologics S.A. 1.04 Million EUR 88.836%
Transgene SA 17 Thousand EUR -588.235%
Financière de Tubize SA - EUR -Infinity%
UCB SA 2.87 Billion EUR 99.996%
Valneva SE 132.76 Million EUR 99.912%
Vivoryon Therapeutics N.V. - EUR -Infinity%